{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:08:39Z","timestamp":1777489719065,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Beh\u00e7et's uveitis (BU) is a debilitating manifestation of Beh\u00e7et's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU.<\/jats:p>","DOI":"10.1007\/s10792-023-02808-w","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T20:19:17Z","timestamp":1688761157000},"page":"4373-4381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Optimizing glucocorticoid therapy for Beh\u00e7et's uveitis: efficacy, adverse effects, and advances in combination approaches"],"prefix":"10.1007","volume":"43","author":[{"given":"Biao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2808_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/09273948.2013.795228","volume":"21","author":"I Tugal-Tutkun","year":"2013","unstructured":"Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of Beh\u00e7et uveitis. Ocul Immunol Inflamm 21:337\u2013350","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR2","first-page":"S112","volume":"32","author":"G Hatemi","year":"2014","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2014) Beh\u00e7et\u2019s syndrome: a critical digest of the 2013\u20132014 literature. Clin Exp Rheumatol 32:S112\u2013S122","journal-title":"Clin Exp Rheumatol"},{"key":"2808_CR3","first-page":"S140","volume":"32","author":"A Vaiopoulos","year":"2014","unstructured":"Vaiopoulos A, Sfikakis P, Kanakis M, Vaiopoulos G, Kaklamanis P (2014) Gastrointestinal manifestations of Beh\u00e7et\u2019s disease: advances in evaluation and management. Clin Exp Rheumatol 32:S140\u2013S148","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2808_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s1474-4422(09)70015-8","volume":"8","author":"A Al-Araji","year":"2009","unstructured":"Al-Araji A, Kidd DP (2009) Neuro-Beh\u00e7et\u2019s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192\u2013204. https:\/\/doi.org\/10.1016\/s1474-4422(09)70015-8","journal-title":"Lancet Neurol"},{"key":"2808_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2808_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/03009742.2021.1904622","volume":"51","author":"M Torgutalp","year":"2022","unstructured":"Torgutalp M, Ero\u011flu D\u015e, Sezer S, Yayla ME, Karata\u015f G, \u00d6zel EM, Din\u00e7er A, Y\u00fcksel ML, G\u00fcl\u00f6ks\u00fcz E, Y\u0131lmaz R, Turgay TM, K\u0131n\u0131kl\u0131 G, Ate\u015f A (2022) Patient characteristics in Beh\u00e7et\u2019s Syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases. Scand J Rheumatol 51(1):50\u201358. https:\/\/doi.org\/10.1080\/03009742.2021.1904622","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"2808_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH (2012) Epidemiology of Beh\u00e7et disease. Ocul Immunol Inflamm 20(5):324\u2013335. https:\/\/doi.org\/10.3109\/09273948.2012.723112","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"2808_CR8","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/bjo.2007.124875","volume":"91","author":"H Keino","year":"2007","unstructured":"Keino H, Okada AA (2007) Beh\u00e7et\u2019s disease: global epidemiology of an Old Silk Road disease. Br J Ophthalmol 91(12):1573\u20131574. https:\/\/doi.org\/10.1136\/bjo.2007.124875","journal-title":"Br J Ophthalmol"},{"key":"2808_CR9","first-page":"68","volume":"36","author":"G Lopalco","year":"2018","unstructured":"Lopalco G, Venerito V, Sota J, Rigante D, Guerriero S, Orlando I, Franceschini R, Favale R, Lapadula G, Castelli B, Frediani B, Galeazzi M, La Torre F, Iannone F, Tosi GM, Fabiani C, Cantarini L (2018) Epidemiological profile of non-infectious uveitis from the rheumatologist\u2019s perspective: a survey from two tertiary referral centres in Italy. Clin Exp Rheumatol 36:68\u201373","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2808_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/09273948.2016.1196714","volume":"26","author":"FN Yal\u00e7\u0131nda\u011f","year":"2018","unstructured":"Yal\u00e7\u0131nda\u011f FN, \u00d6zdal PC, \u00d6zyazgan Y et al (2018) Demographic and clinical characteristics of uveitis in Turkey: the first national registry report. Ocul Immunol Inflamm 26(1):17\u201326","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR11","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s10067-015-3161-1","volume":"35","author":"H Wang","year":"2016","unstructured":"Wang H, Guo X, Tian Z, Liu Y, Wang Q, Li M, Zeng X, Fang Q (2016) Intracardiac thrombus in patients with Behcet\u2019s disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. Clin Rheumatol 35:2501\u20132507","journal-title":"Clin Rheumatol"},{"key":"2808_CR12","first-page":"2547","volume":"95","author":"F Zhang","year":"2015","unstructured":"Zhang F, Su M, Zhang B, Dong Y, Li P (2015) Clinical features and disease activity index of Beh\u00e7et\u2019s disease. Zhonghua Yi Xue Za Zhi 95:2547\u20132550","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2808_CR13","first-page":"44","volume":"53","author":"H Wu","year":"2014","unstructured":"Wu H, Li G, Chen H, Zheng W, Zhang M, Zhao Y (2014) A clinical analysis of ocular involvement in 111 cases of Behcet\u2019s disease. Zhonghua Nei Ke Za Zhi 53:44\u201347","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2808_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","volume":"152","author":"SR Taylor","year":"2011","unstructured":"Taylor SR, Singh J, Menezo V, Wakefield D, McCluskey P, Lightman S (2011) Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 152:1059\u20131066","journal-title":"Am J Ophthalmol"},{"key":"2808_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2017.1351570","volume":"27","author":"K Pathanapitoon","year":"2019","unstructured":"Pathanapitoon K, Kunavisarut P, Saravuttikul FA, Rothova A (2019) Ocular Manifestations and Visual Outcomes of Behcet\u2019s Uveitis in a Thai population. Ocul Immunol Inflamm 27:2\u20136. https:\/\/doi.org\/10.1080\/09273948.2017.1351570","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR16","doi-asserted-by":"publisher","first-page":"6872402","DOI":"10.1155\/2020\/6872402","volume":"2020","author":"J Sota","year":"2020","unstructured":"Sota J, Cantarini L, Vitale A, Sgheri A, Gentileschi S, Caggiano V, Gelardi V, Frediani B, Tosi GM, Fabiani C (2020) Long-term outcomes of Behcet\u2019s syndrome-related uveitis: a monocentric Italian experience. Mediators Inflamm 2020:6872402. https:\/\/doi.org\/10.1155\/2020\/6872402","journal-title":"Mediators Inflamm"},{"key":"2808_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH (2012) Epidemiology of Beh\u00e7et disease. Ocul Immunol Inflamm 20:324\u2013335","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1756-185X.2010.01549.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Larimi R, Ashofteh F (2010) Behcet\u2019s disease in Iran: analysis of 6500 cases. Int J Rheum Dis 13:367\u2013373","journal-title":"Int J Rheum Dis"},{"key":"2808_CR19","first-page":"S145","volume":"33","author":"SN Esatoglu","year":"2015","unstructured":"Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF (2015) A reappraisal of the association between Beh\u00e7et\u2019s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol 33:S145-151","journal-title":"Clin Exp Rheumatol"},{"key":"2808_CR20","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3760\/cma.j.issn.0376-2491.2016.19.013","volume":"96","author":"N Gao","year":"2016","unstructured":"Gao N, Han W, Ci WP, Liao H, Du J (2016) Clinical data analysis of cardiovascular involvement in Behcet\u2019s disease. Zhonghua Yi Xue Za Zhi 96:1523\u20131526. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2016.19.013","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2808_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00417-017-3667-0","volume":"255","author":"R Amer","year":"2017","unstructured":"Amer R, Alsughayyar W, Almeida D (2017) Pattern and causes of visual loss in Behcet\u2019s uveitis: short-term and long-term outcomes. Graefes Arch Clin Exp Ophthalmol 255:1423\u20131432. https:\/\/doi.org\/10.1007\/s00417-017-3667-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2808_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, Van Damme J (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139:177\u2013184. https:\/\/doi.org\/10.1016\/j.clim.2011.01.014","journal-title":"Clin Immunol"},{"key":"2808_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study. Br J Ophthalmol 91:1579\u20131582","journal-title":"Br J Ophthalmol"},{"key":"2808_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-017-0681-6","volume":"12","author":"TW McNally","year":"2017","unstructured":"McNally TW, Damato EM, Murray PI, Denniston AK, Barry RJ (2017) An update on the use of biologic therapies in the management of uveitis in Beh\u00e7et\u2019s disease: a comprehensive review. Orphanet J Rare Dis 12:130","journal-title":"Orphanet J Rare Dis"},{"key":"2808_CR25","first-page":"9","volume":"3","author":"FZ Shahneh","year":"2013","unstructured":"Shahneh FZ, Mohammadian M, Babaloo Z, Baradaran B (2013) New approaches in immunotherapy of Behcet disease. Adv Pharm Bull 3:9","journal-title":"Adv Pharm Bull"},{"key":"2808_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/09273940802553279","volume":"17","author":"HG Yu","year":"2009","unstructured":"Yu HG, Kim MJ, Oh FS (2009) Fluorescein angiography and visual acuity in active uveitis with Beh\u00e7et disease. Ocul Immunol Inflamm 17:41\u201346","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR27","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","volume":"246","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Cing\u00fc K, Kir N, Yeniad B, Urgancioglu M, G\u00fcl A (2008) Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol 246:1169\u20131177","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2808_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/bjo.82.6.704","volume":"82","author":"RM Stanbury","year":"1998","unstructured":"Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy\u2014side effects and their management. Br J Ophthalmol 82:704\u2013708","journal-title":"Br J Ophthalmol"},{"key":"2808_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000336676","volume":"51","author":"P LeHoang","year":"2012","unstructured":"LeHoang P (2012) The gold standard of noninfectious uveitis: corticosteroids. New Treat Noninfect Uveitis 51:7\u201328","journal-title":"New Treat Noninfect Uveitis"},{"key":"2808_CR30","doi-asserted-by":"publisher","first-page":"871019","DOI":"10.1155\/2012\/871019","volume":"2012","author":"E Alpsoy","year":"2012","unstructured":"Alpsoy E (2012) New evidence-based treatment approach in Behcet\u2019s disease. Patholog Res Int 2012:871019. https:\/\/doi.org\/10.1155\/2012\/871019","journal-title":"Patholog Res Int"},{"key":"2808_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajo.2004.02.053","volume":"138","author":"M Karacorlu","year":"2004","unstructured":"Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E (2004) Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol 138:289\u2013291. https:\/\/doi.org\/10.1016\/j.ajo.2004.02.053","journal-title":"Am J Ophthalmol"},{"key":"2808_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/jop.2007.0015","volume":"23","author":"S Tuncer","year":"2007","unstructured":"Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I (2007) Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh\u00e7et disease. J Ocul Pharmacol Ther 23:395\u2013401","journal-title":"J Ocul Pharmacol Ther"},{"key":"2808_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00002281-200207000-00001","volume":"14","author":"TM Martin","year":"2002","unstructured":"Martin TM, Smith JR, Rosenbaum JT (2002) Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 14:337\u2013341. https:\/\/doi.org\/10.1097\/00002281-200207000-00001","journal-title":"Curr Opin Rheumatol"},{"key":"2808_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ajo.2011.02.009","volume":"152","author":"HA Leder","year":"2011","unstructured":"Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE (2011) Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 152:441\u2013448. https:\/\/doi.org\/10.1016\/j.ajo.2011.02.009","journal-title":"Am J Ophthalmol"},{"key":"2808_CR35","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2147\/OPTH.S89341","volume":"10","author":"HY Tan","year":"2016","unstructured":"Tan HY, Agarwal A, Lee CS, Chhablani J, Gupta V, Khatri M, Nirmal J, Pavesio C, Agrawal R (2016) Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol 10:1983\u20132020. https:\/\/doi.org\/10.2147\/OPTH.S89341","journal-title":"Clin Ophthalmol"},{"key":"2808_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00417-006-0514-0","volume":"245","author":"LS Atmaca","year":"2007","unstructured":"Atmaca LS, Yal\u00e7inda\u011f FN, \u00d6zdemir \u00d6 (2007) Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol 245:451\u2013456","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2808_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/09273948.2013.829109","volume":"22","author":"UC Park","year":"2014","unstructured":"Park UC, Park JH, Yu HG (2014) Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Beh\u00e7et disease. Ocul Immunol Inflamm 22:27\u201333","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, K\u00f6tter I, Wallace GR, Murray PI, St\u00fcbiger N, Zierhut M (2008) Beh\u00e7et\u2019s disease: ocular effects and treatment. Prog Retin Eye Res 27:111\u2013136","journal-title":"Prog Retin Eye Res"},{"key":"2808_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","volume":"117","author":"C Pavesio","year":"2010","unstructured":"Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW, Fluocinolone Acetonide Study Group (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117:567\u2013575. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.027","journal-title":"Ophthalmology"},{"key":"2808_CR40","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archophthalmol.2011.1425","volume":"130","author":"ZM Ahmad","year":"2012","unstructured":"Ahmad ZM, Hughes BA, Abrams GW, Mahmoud TH (2012) Combined posterior chamber intraocular lens, vitrectomy, Retisert, and pars plana tube in noninfectious uveitis. Arch Ophthalmol 130:908\u2013913. https:\/\/doi.org\/10.1001\/archophthalmol.2011.1425","journal-title":"Arch Ophthalmol"},{"key":"2808_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcjo.2014.03.004","volume":"49","author":"EK Oh","year":"2014","unstructured":"Oh EK, Lee EK, Yu HG (2014) Long-term results of fluocinolone acetonide intravitreal implant in Beh\u00e7et intractable posterior uveitis. Can J Ophthalmol 49:273\u2013278","journal-title":"Can J Ophthalmol"},{"key":"2808_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE et al (2019) Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular Edema: the periocular versus intravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283\u2013295","journal-title":"Ophthalmology"},{"issue":"10","key":"2808_CR43","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","volume":"127","author":"GJ Jaffe","year":"2020","unstructured":"Jaffe GJ, Pavesio CE (2020) Study Investigators. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127(10):1395\u20131404. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.001","journal-title":"Ophthalmology"},{"issue":"5","key":"2808_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","volume":"128","author":"O Tomkins-Netzer","year":"2021","unstructured":"Tomkins-Netzer O, Lightman SL, Burke AE, Sugar EA, Lim LL, Jaffe GJ, Follow-up Study Research Group (2021) Seven-year outcomes of uveitic macular edema: the multicenter uveitis steroid treatment trial and follow-up study results. Ophthalmology 128(5):719\u2013728","journal-title":"Ophthalmology"},{"key":"2808_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2021.1954199","volume":"18","author":"PT Merrill","year":"2021","unstructured":"Merrill PT, Henry CR, Nguyen QD, Reddy A, Kapik B, Ciulla TA (2021) Suprachoroidal CLS-TA with and without systemic corticosteroid and\/or steroid-sparing therapy: a post-hoc analysis of the phase 3 PEACHTREE clinical trial. Ocul Immunol Inflamm 18:1\u20138","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR46","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1167\/iovs.12-10981","volume":"54","author":"S Lightman","year":"2013","unstructured":"Lightman S, Belfort R Jr, Naik RK, Lowder C, Foster CS, Rentz AM, Cui H, Whitcup SM, Kowalski JW, Revicki DA (2013) Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 54:4864\u20134870. https:\/\/doi.org\/10.1167\/iovs.12-10981","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2808_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/09273948.2015.1042167","volume":"23","author":"E Co\u015fkun","year":"2015","unstructured":"Co\u015fkun E, Celemler P, Kimyon G, \u00d6ner V, Kisacik B, Erbagci I, Onat AM (2015) Intravitreal dexamethasone implant for treatment of refractory Beh\u00e7et posterior uveitis: one-year follow-up results. Ocul Immunol Inflamm 23:437\u2013443","journal-title":"Ocul Immunol Inflamm"},{"key":"2808_CR48","first-page":"415","volume":"19","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Emmi G, Lopalco G, Vannozzi L, Bacherini D, Guerriero S, Franceschini R, Frediani B, Iannone F, Marco Tosi G et al (2017) Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behcet\u2019s Disease. Isr Med Assoc J 19:415\u2013419","journal-title":"Isr Med Assoc J"},{"key":"2808_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004397-200604620-00017","volume":"46","author":"PA Yates","year":"2006","unstructured":"Yates PA, Michelson JB (2006) Beh\u00e7et disease. Int Ophthalmol Clin 46:209\u2013233","journal-title":"Int Ophthalmol Clin"},{"key":"2808_CR50","doi-asserted-by":"publisher","first-page":"AB152","DOI":"10.1016\/j.jaci.2009.12.597","volume":"125","author":"A Ariza","year":"2010","unstructured":"Ariza A, Aranda A, Do\u00f1a I, Blanca-L\u00f3pez N, Canto G, Mayorga C, Blanca M, Torres M (2010) IgE-mediated hypersensitivity reactions to methylprednisolone. J Allergy Clin Immunol 125:AB152","journal-title":"J Allergy Clin Immunol"},{"key":"2808_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, Haussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61\u201398. https:\/\/doi.org\/10.2165\/00003088-200544010-00003","journal-title":"Clin Pharmacokinet"},{"key":"2808_CR52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/1756-185X.13095","volume":"20","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F (2017) High-dose intravenous steroid pulse therapy in ocular involvement of Behcet\u2019s disease: a pilot double-blind controlled study. Int J Rheum Dis 20:1269\u20131276","journal-title":"Int J Rheum Dis"},{"key":"2808_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12009-007-0018-5","volume":"39","author":"FN Yal\u00e7indag","year":"2007","unstructured":"Yal\u00e7indag FN, Can E, \u00d6zdemir \u00d6 (2007) Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Beh\u00e7et\u2019s disease. Ann Ophthalmol 39:194\u2013197","journal-title":"Ann Ophthalmol"},{"key":"2808_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1517\/14728214.2011.537824","volume":"16","author":"T Larson","year":"2011","unstructured":"Larson T, Nussenblatt RB, Sen HN (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16:309\u2013322. https:\/\/doi.org\/10.1517\/14728214.2011.537824","journal-title":"Expert Opin Emerg Drugs"},{"key":"2808_CR55","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, K\u00f6tter I, Leccese P (2018) 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 77:808\u2013818","journal-title":"Ann Rheum Dis"},{"key":"2808_CR56","first-page":"737","volume":"64","author":"CD Herman","year":"1989","unstructured":"Herman CD (1989) Uveitis: a clinical approach to diagnosis and management. Brit J Ophthalmol 64:737\u2013738","journal-title":"Brit J Ophthalmol"},{"key":"2808_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/BTT.S41477","volume":"8","author":"S Pasadhika","year":"2014","unstructured":"Pasadhika S, Rosenbaum JT (2014) Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 8:67\u201381. https:\/\/doi.org\/10.2147\/BTT.S41477","journal-title":"Biologics"},{"issue":"312\u2013318","key":"2808_CR58","volume":"115","author":"P Yang","year":"2008","unstructured":"Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of Chinese patients with Beh\u00e7et\u2019s disease. Ophthalmology 115(312\u2013318):e314","journal-title":"Ophthalmology"},{"key":"2808_CR59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C (2005) Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol 50:297\u2013350","journal-title":"Surv Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02808-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:08:50Z","timestamp":1695640130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02808-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2808"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02808-w","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This study is a literature review and does not involve human participants, human data, or human tissue.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not contain any individual person's data in any form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}